RocheRHHBY announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib). Data from the study showed that Cotellic in combination with Zelboraf, enabled patients with previously untreated BRAF V600 mutation positive advanced melanoma